A comprehensive review of wearable blood pressure monitoring reveals significant accuracy gaps in smartwatches that attempt to measure systolic and diastolic pressures outside controlled clinical settings, highlighting the need for cautious interpretation by users and clinicians alike.

Researchers note that readings can be influenced by motion, temperature, wrist position, skin contact quality, and device calibration, leading to inconsistent measurements during daily activities such as exercise and sleep.

Acknowledging these constraints, the study emphasizes that cuffless devices should complement traditional cuff based methods rather than replace cuff based measurements for critical clinical decisions and medication adjustments.

The report highlights software limitations, including calibration drift, algorithm variability, and differences in performance across user skin tones, ages, and device generations, which can skew trend analysis over time.

In September 2025, the U.S. FDA cleared the Apple Watch Hypertension Notifications Feature, a cuffless tool that uses optical sensors and signal processing to estimate blood pressure and alert users to potentially elevated readings, though exact accuracy often depends on proper use and context.

Industry experts stress the need for transparent labeling, robust user education, and rigorous validation studies to help consumers interpret smartwatch readings without overreacting or neglecting professional evaluations.

The analysis concludes that while wearable blood pressure monitoring holds meaningful promise for continuous awareness and early detection, medical grade cuff measurements remain the standard when precise pressures determine treatment choices and clinical decisions.